dc.contributor.author |
J-Khemlani, Adrina Hema |
|
dc.contributor.author |
Pilapitiya, Devaki |
|
dc.contributor.author |
Tsai, Catherine Jia-Yun |
|
dc.contributor.author |
Proft, Thomas |
|
dc.contributor.author |
Loh, Jacelyn Mei San |
|
dc.coverage.spatial |
United States |
|
dc.date.accessioned |
2023-08-02T03:53:43Z |
|
dc.date.available |
2023-08-02T03:53:43Z |
|
dc.date.issued |
2023-03 |
|
dc.identifier.citation |
(2023). Immunology and Cell Biology. |
|
dc.identifier.issn |
0818-9641 |
|
dc.identifier.uri |
https://hdl.handle.net/2292/65219 |
|
dc.description.abstract |
Group A Streptococcus (GAS) is a human pathogenic bacterium that can trigger a wide range of diseases, including the autoimmune diseases acute rheumatic fever and rheumatic heart disease, causing major morbidity and mortality in many low- and middle-income countries. Primary intervention programs have had limited success thus far, and a licensed vaccine has yet to be developed. The pilus of GAS is known to be involved in host cell adhesion, biofilm formation and immune evasion. We have a mucosal vaccine in development that expresses the pilus of GAS on the surface of the nonpathogenic bacterium Lactococcus lactis. To expand strain coverage, we combined seven L. lactis constructs, each expressing a different GAS pilus variant, and investigated the systemic and mucosal immune responses following immunization. Mice immunized with this combination showed specific immunoglobin G and immunoglobin A responses to the GAS pilus proteins of vaccine strains, at levels comparable to mice immunized with a single construct. Cross-reactivity to pilus proteins of nonvaccine strains was also evident. Furthermore, protective efficacy against a homologous strain of GAS in a murine nasopharyngeal colonization model was observed. Overall, this study provides further evidence for using pilus-expressing lactic acid bacteria as a vaccine to prevent upper respiratory tract GAS infections. |
|
dc.format.medium |
Print-Electronic |
|
dc.language |
eng |
|
dc.publisher |
Wiley |
|
dc.relation.ispartofseries |
Immunology and cell biology |
|
dc.rights |
Items in ResearchSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Previously published items are made available in accordance with the copyright policy of the publisher. |
|
dc.rights.uri |
https://researchspace.auckland.ac.nz/docs/uoa-docs/rights.htm |
|
dc.rights.uri |
http://creativecommons.org/licenses/by-nc-nd/4.0/ |
|
dc.subject |
Group A Streptococcus |
|
dc.subject |
Lactococcus lactis |
|
dc.subject |
Streptococcus pyogenes |
|
dc.subject |
mucosal vaccine |
|
dc.subject |
pilus |
|
dc.subject |
Biotechnology |
|
dc.subject |
Infectious Diseases |
|
dc.subject |
Prevention |
|
dc.subject |
Immunization |
|
dc.subject |
Vaccine Related |
|
dc.subject |
2.1 Biological and endogenous factors |
|
dc.subject |
2 Aetiology |
|
dc.subject |
Infection |
|
dc.subject |
3 Good Health and Well Being |
|
dc.subject |
0601 Biochemistry and Cell Biology |
|
dc.subject |
1107 Immunology |
|
dc.title |
Expanding strain coverage of a group A Streptococcus pilus-expressing Lactococcus lactis mucosal vaccine. |
|
dc.type |
Journal Article |
|
dc.identifier.doi |
10.1111/imcb.12643 |
|
dc.date.updated |
2023-07-06T05:08:33Z |
|
dc.rights.holder |
Copyright: The authors |
en |
dc.identifier.pmid |
36967611 (pubmed) |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/36967611 |
|
pubs.publication-status |
Published |
|
dc.rights.accessrights |
http://purl.org/eprint/accessRights/OpenAccess |
en |
pubs.subtype |
Journal Article |
|
pubs.elements-id |
955924 |
|
pubs.org-id |
Medical and Health Sciences |
|
pubs.org-id |
Science |
|
pubs.org-id |
Science Research |
|
pubs.org-id |
Medical Sciences |
|
pubs.org-id |
Molecular Medicine |
|
pubs.org-id |
Maurice Wilkins Centre (2010-2014) |
|
dc.identifier.eissn |
1440-1711 |
|
pubs.record-created-at-source-date |
2023-07-06 |
|
pubs.online-publication-date |
2023-03-26 |
|